A new series of heteroleptic copper( ii ) complexes with terpyridines and naproxen are reported. The results of biological activity are laying a foundation for the design of new anticancer agents.
No takes yet. Share an insight, caveat, or question.
Dharmasivam et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: